NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Taysha Gene Therapies, Inc. TSHA
6 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$9.8M
▲ 17.3% vs FY2024
EPS · FY25
$-0.34
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-68.5%
Net margin · FY25
-1115.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 9.8M
Revenue, FY2025 · full 6-year series below
Revenue
Net income
The company lost 1115 cents on every revenue dollar this year.
Per share
USD -0.34
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-68.5%
Return on equity, FY2025
ROE
Operating margin-1130.6%
Net margin-1115.3%
Return on assets-43.3%
Each USD of equity lost 68 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+57.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.29B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 343.3M
total assets, end of FY2025
Total assetsUSD 343.3M
EquityUSD 246.9M
CashUSD 319.8M
Gross debtUSD 50.1M
Net debtUSD -269.7M
Current ratio12.23×
The company holds more cash than debt.
History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
Revenue $B
0.0
0.0
0.0
0.0
·
·
Operating income $B
−0.1
−0.1
−0.1
−0.2
−0.2
−0.0
EBITDA $B
−0.1
−0.1
−0.1
−0.2
−0.2
−0.0
Income tax $B
0.0
0.0
0.0
0.0
·
0.0
Net income $B
−0.1
−0.1
−0.1
−0.2
−0.2
−0.1
EPS, diluted $
−0.34
−0.36
−0.96
−3.78
−4.64
−3.40
Dividend / sh $
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
−68.5
−121.9
−294.0
−344.7
−100.7
−23.9
Shares out B
0.29
0.20
0.19
0.06
0.04
0.04
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
18 of 18
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed